Theragen Bio announced that it was selected as a business operator for the development of AI integrated software (SW) solution for multi-faceted analysis of rare pediatric diseases along with Seoul National University Hospital and Kakao Healthcare Consortium.
A total of 9.7 billion won in research expenses will be invested over three years from this year to 2024 in the ‘Development of AI integrated SW solution for multi-faceted analysis of rare diseases in children’ project hosted by the Information and Communication Technology Planning and Evaluation Institute. The goal is to develop cloud-based software solutions, including diagnostic artificial intelligence models and prognosis management artificial intelligence models for nine rare pediatric disease groups. A total of 5 hospitals, including Seoul National University Hospital, Seoul St. Mary’s Hospital, Samsung Seoul Hospital, Pusan National University Hospital, and Kyungpook National University Hospital, and 4 SW development companies including Theragen Bio and Kakao Healthcare are participating.
In this project, Theragen Bio plans to produce sequencing data to ▲ propose treatment solutions for patients with rare diseases and ▲ verify diagnostic software. To this end, we analyze approximately 33 million biomedical literature using artificial intelligence technology, conduct text mining of rare pediatric diseases, and develop an algorithm that proposes diagnosis and treatment solutions. In addition, a total of 13 hospitals, including 8 national clinical verification network hospitals, including Chungbuk National University Hospital, Inha University Hospital, Chungnam National University Hospital, Boramae Hospital, Jeju National University Hospital, Ajou University Hospital, and St. Vincent Hospital, administered 900 patients to verify artificial intelligence software for rare pediatric diseases. The plan is to build full-length genome data for Korea.
Hwang Tae-soon, CEO of Theragen Bio, said, “The reason Theragen Bio was selected for this SW project is that the company participated as a consortium in both the first and second rounds of the bio big data preliminary project under the jurisdiction of the Ministry of Science and ICT, the Ministry of Commerce, Industry and Energy, and the Ministry of Health and Welfare, and produced 25,000 genomes. “This is because we have experience in producing data,” he said. “We are happy to be able to contribute to the accurate and rapid diagnosis of patients with rare pediatric diseases through Theragen Bio’s abundant experience in genome analysis and to strengthen corporate social responsibility.” “In the future, we will become a company that contributes to technological development that benefits the world.”
Meanwhile, based on its experience in establishing an international rare disease information exchange platform with the Korea Disease Control and Prevention Agency and Seoul National University Hospital, Theragen Bio is participating in the ‘Lee Kun-hee Foundation Project’, which has been implemented since April 2021, with 81 base hospitals in each region of Korea and a central diagnostic institution. Together with Seoul National University Hospital, we are building a platform where rare disease researchers can share their experiences. In Korea, the number of patients (including family members) suffering from rare diseases is close to 800,000, and the clinical symptoms are so diverse that even experienced specialists face many difficulties as they are unable to prescribe proper treatment in a timely manner. It is known.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news